Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study

BMC Psychiatry

Heinz Grunze²  Stefan Wilhelm¹  Hans-Peter Hundemer¹  Carsten Henneges¹  Steffen Eppendorfer¹  Anette Minarzyk¹  Susanne Kraemer¹ 

[1] Lilly Deutschland GmbH, Medical Department, Werner-Reimers-Str. 2-4, 61352 Bad Homburg, Germany;Newcastle University; Institute of Neuroscience, Newcastle, UK

关键词: Medication regimen;    Out-patient setting;    Relapse;    Retention;    Bipolar disorder;   

Others  :  1124000
DOI  :  10.1186/1471-244X-13-193

 received in 2012-10-30, accepted in 2013-05-07,  发布年份 2013

【 摘 要 】

Background

Although a range of pharmacotherapeutical options are available for the treatment of bipolar disorder, patient non-adherence to prescribed treatment regimens and early treatment discontinuation remain among the primary obstacles to effective treatment. Therefore, this observational study assessed time on mood stabilizing medication and retention rates in patients with bipolar disorder (BD).

Methods

In an 18-month, prospective, multicenter, non-interventional study conducted in Germany 761 outpatients (≥18 years) with BD and on maintenance therapy were documented. For analysis, patients were stratified by baseline medication: monotherapy olanzapine (OM, N = 186), lithium (LM, N = 152), anticonvulsants (N = 216), other mood stabilizing medication (OMS, N = 44); combination therapy olanzapine/lithium (N = 47), olanzapine/anticonvulsant (N = 68), other combinations (OC, N = 48). Continuation on medication was assessed as retention rates with 95% confidence intervals. Time to discontinuation and relapse-free time were calculated by Kaplan-Meier analysis. A relapse was defined as increase to CGI-BP >3, worsening of CGI-BP by ≥2 points, hospitalization or death related to BD. A Cox regression was calculated for the discontinuation of mood stabilizing therapy (reference: OM). Logistic regression models with stepwise forward selection were used to explore possible predictors of maintenance of treatment and relapse.

Results

After 540 days (18 months), the overall retention rate of baseline medication was 87.7%, without notable differences between the cohorts. The overall mean time on mood stabilizing treatment was 444.7 days, with a range of 377.5 (OMS) to 481 (LM) by cohort. 74.0% of all patients were without relapse, with rates between the cohorts ranging from 58.4% (OC) to 80.2% (LM).

Conclusions

Retention rates exceeded controlled trial results in all treatment cohorts, in addition to other explanations possibly reflecting that the physicians were expertly adapting treatment regimens to the individual patient’s disease characteristics and special needs.

【 授权许可】

   
2013 Kraemer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]World Health Organisation (WHO): World Health Report 2001: Mental Health: New understanding, new hope. 2001. Available at: http://www.who.int/whr/2001/en/annex3_en.pdf webcite. Accessed August 29, 2012
• [2]Runge C, Grunze H: Jährliche Krankheitskosten bipolarer Störungen in Deutschland. Nervenarzt 2004, 75:896-903.
• [3]Grunze H, Dargel S: Acute and long-term treatment for bipolar disorder. Nervenarzt 2010, 81:539-548.
• [4]Greenhouse WJ, Meyer B, Johnson SL: Coping and medication adherence in bipolar disorder. J Affect Disord 2000, 59:237-241.
• [5]Jamison KR, Gerner RH, Goodwin FK: Patient and physician attitudes towards lithium: relationship to compliance. Arch Gen Psychiatry 1979, 36:866-869.
• [6]Grunze H, Vieta E, Goodwin GM, et al.: The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010, 11:81-109.
• [7]Keck PE, McElroy SL, Strakowski SM, et al.: 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998, 155:646-652.
• [8]Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK, Valproate V: Lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011, 199:57-63.
• [9]Kessing LV, Hellmund G, Andersen PK: An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorders. J Psychopharmacol 2012, 26(5):644-65223.
• [10]Keck PE, McElroy SL, Strakowski SM, et al.: Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997, 33:87-91.
• [11]Keck PE, McElroy SL, Strakowski SM, et al.: Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996, 57:147-151.
• [12]Tohen M, Calabrese JR, Sachs GS, et al.: Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006, 163:247-256.
• [13]Suppes T, Vieta E, Liu S, et al.: Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009, 166:476-488.
• [14]National Institute of Health and Clinical Excellence (NICE): Clinical guideline 38: Bipolar disorder. July 2006. Available at: http://www.nice.org.uk/nicemedia/live/10990/30193/30193.pdf webcite. Accessed August 29, 2012
• [15]Goodwin M: Consensus group of the British association for psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British association for psychopharmacology. J Psychopharmacol 2009, 23:346-388.
• [16]Yatham LN, Kennedy SH, Schaffer A, et al.: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009, 11:225-255.
• [17]Tohen M, Chengappa KNR, Suppes T, et al.: Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004, 184:337-345.
• [18]Collegium Internationale Psychiatriae Scalarum (CIPS): Internationale Skalen für Psychiatrie (4 Auflage). Göttingen: Beltz-Test GmbH; 1996.
• [19]Spearing MK, Post RM, Leverich GS, et al.: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997, 73:159-171.
• [20]International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Version for 2010. Available at: http://apps.who.int/classifications/apps/icd/icd10online webcite. Accessed August 29 2012
• [21]Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177-183.
• [22]Wilhelm S, Schacht A, Minarzyk A, et al.: Preventing bipolar relapse: which factors are associated with different mood stabilizer therapy? Analysis of baseline data from a German observational study. Eur Psychiatry 2007, 22(Suppl):144. AEP 2007, Madrid
• [23]Kessing LV, Søndergård L, Kvist K, Andersen PK: Adherence to lithium innaturalistic settings: results from a nationwide pharmacoepidemiological study. Bipolar Disord 2007, 9:730-736.